The startup develops genome detection and analysis technology that utilizes enhancers and m-ribonucleic acid to create diagnostic drugs. Their platform enables pharmaceutical companies to analyze ribonucleic acid transcript expression fluctuations, facilitating the early diagnosis of infectious diseases through collaboration with external organizations and academia.
Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic methods for infertility and recurrent pregnancy loss often fail to identify underlying causes related to immune system dysfunction. Existing blood tests may not detect specific autoantibodies that contribute to these conditions, leaving a significant portion of patients without a clear diagnosis or targeted treatment options. This can lead to prolonged time to conception and increased emotional distress for affected individuals.
Solution
AOI Biosciences (formerly Revorf) offers the β2GPI Neoself Antibody Test, a novel blood test designed to identify neo-self antibodies associated with infertility and recurrent pregnancy loss. The test utilizes a proprietary technology based on the neo-self theory, which posits that certain autoantibodies can trigger miscarriage and thrombosis. By detecting these previously undetectable antibodies, the test enables clinicians to identify patients who may benefit from targeted therapies, such as anticoagulants or immunomodulatory treatments. The company also leverages advanced bioinformatic analysis and quantum-inspired computing to support drug discovery and development for autoimmune diseases.
Target Audience
The primary target audience includes fertility clinics, reproductive endocrinologists, and obstetricians specializing in recurrent pregnancy loss, as well as pharmaceutical companies developing drugs for autoimmune diseases.
Features
- Detects β2GPI neo-self antibodies in blood samples with high sensitivity
- Identifies patients with a predisposition to thrombosis and pregnancy complications
- Provides clinicians with actionable insights for personalized treatment strategies
- Supports research and development of novel therapeutics for autoimmune disorders
- Offers contract research services for biomarker discovery and drug target validation
- Employs quantum-inspired optimization solutions for allosteric drug design